In this study, we examined the effects of targeting PFKFB3 with genetic knockdown or with glycolytic inhibitor PFK158 (a specific inhibitor of PFKFB3) on cancer stemness, YAP/TAZ signaling, EMT, and therapeutic resistance for SCLC in vitro and in vivo. This evidence concerns the gene YAP1 and cancer.